

encompassed by Examiner's Groups VI and VII (claims 5-12, drawn to IncA *C. trachomatis* and *C. psittaci*, SEQ ID NOs: 8 and 14).

AMENDMENT

In the Specification

Please insert the following header and paragraph at the top of page one, immediately following the title:

--CROSS REFERENCE TO RELATED APPLICATIONS

B₁ This is a National Stage of International Application No. PCT/US99/08744, filed April 20, 1999, which claims the benefit of U.S. Provisional Applications No. 60/082,438, filed April 20, 1998, No. 60/082,588, filed April 21, 1998, and No. 60/086,450, filed May 22, 1998.--

In the Claims

Please cancel claims 1-4

5. (amended) A vaccine preparation comprising at least one purified peptide comprising at least 5 contiguous amino acids of an amino acid sequence as set forth as SEQ ID NO: 8 or SEQ ID NO: 14.

B₂ 6. (amended) The vaccine preparation of claim 5 wherein the at least one peptide comprises at least 10 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 8 or SEQ ID NO: 14.

7. (amended) The vaccine preparation of claim 5 wherein the at least one peptide comprises at least 15 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 8 or SEQ ID NO: 14.

8. (amended) The vaccine preparation of claim 5 wherein the at least one peptide comprises at least 20 contiguous amino acids of the amino acid sequence set forth as SEQ ID NO: 8 or SEQ ID NO: 14.

9. (amended) A vaccine preparation comprising at least one purified peptide comprising an amino acid sequence as set forth as SEQ ID NO: 8, or SEQ ID NO: 14.

B2 10. (amended) A method of making a vaccine comprising combining a pharmaceutically acceptable excipient with at least one purified peptide having an amino acid sequence as set forth as SEQ ID NO:8 or SEQ ID NO:14.

11. (reiterated) A method of vaccination, comprising administering a vaccine preparation according to claim 5 to a mammal.

12. (reiterated) A method of vaccination, comprising administering a vaccine preparation according to claim 9 to a mammal.

Please cancel claims 13-18.

Please add the following new claims:

19. (new) The method of claim 11, wherein the mammal is a human.

20. (new) The method of claim 12, wherein the mammal is a human.

B3
SUB
C 21. (new) A composition for inducing an immune response in a subject, comprising at least one purified peptide comprising at least 5 contiguous amino acids of an amino acid sequence as set forth as SEQ ID NO: 8 or SEQ ID NO: 14.

22. (new) The composition of claim 21 wherein the sequence of the at least one peptide comprises at least 10 contiguous amino acids of at least one of the specified sequences.

sub D1 23. (new) The composition of claim 21 wherein the sequence of the at least one peptide comprises at least 15 contiguous amino acids of at least one of the specified sequences.

24. (new) The composition of claim 21 wherein the sequence of the at least one peptide comprises at least 20 contiguous amino acids of at least one of the specified sequences.

B3 concludes 25. (new) A composition for inducing an immune response comprising at least one purified peptide comprising an amino acid sequence as set forth as SEQ ID NO: 8 or SEQ ID NO: 14.

sub C3 26. (new) A method of making a composition for inducing an immune response comprising combining a pharmaceutically acceptable excipient with at least one purified peptide having an amino acid sequence as set forth as SEQ ID NO: 8 or SEQ ID NO: 14.

sub D1 27. (new) A method of inducing an immune response in a subject, comprising administering a composition according to claim 21 to a mammal.

28. (new) A method of inducing an immune response in a subject, comprising administering a composition according to claim 24 to a mammal.

29. (new) The method of claim 26, wherein the mammal is a human.

30. (new) The method of claim 27, wherein the mammal is a human.